https://mindmedicinelaw.com/briefing/loneliness-and-depression-implications-for-future-psychedelic-therapies-20260724-25852The Psychedelic Journalen2026-07-25T22:06:35.963718+00:00Loneliness and Depression: Implications for Future Psychedelic Therapiesloneliness, depression, psychedelic therapies, biopsychosocial mechanisms, clinical trials, mental health treatment, longitudinal study, inpatient treatment, biomarker analysis, social connectednesshttps://mindmedicinelaw.com/briefing/ipsc-study-unveils-shared-effects-of-rapid-acting-antidepressants-20260724-25804The Psychedelic Journalen2026-07-25T22:06:04.879603+00:00iPSC Study Unveils Shared Effects of Rapid-Acting AntidepressantsiPSC-derived neurons, rapid-acting antidepressants, treatment-resistant depression, psychedelics, molecular mechanisms, drug discovery, clinical trials, neuroscience, mental health, ketaminehttps://mindmedicinelaw.com/briefing/ssri-brexpiprazole-interaction-sexual-dysfunction-risks-20260723-25842The Psychedelic Journalen2026-07-25T22:06:42.671958+00:00SSRI-Brexpiprazole Interaction: Sexual Dysfunction RisksSSRI, brexpiprazole, sexual dysfunction, drug-drug interaction, antidepressants, antipsychotics, pharmacovigilance, 5-HT1A receptor, clinical implications, FAERS databasehttps://mindmedicinelaw.com/briefing/pilot-study-explores-personalized-dbs-for-schizophrenia-20260723-25854The Psychedelic Journalen2026-07-25T22:06:26.943037+00:00Pilot Study Explores Personalized DBS for Schizophreniapersonalized deep brain stimulation, treatment-resistant schizophrenia, intracranial circuit-guided DBS, salience network, brain network mapping, psychiatric disordershttps://mindmedicinelaw.com/briefing/evaluating-psilocybin-s-cardiac-safety-for-low-dose-use-20260723-25806The Psychedelic Journalen2026-07-25T22:06:20.409748+00:00Evaluating Psilocybin's Cardiac Safety for Low-Dose Usepsilocybin, cardiac safety, 5-HT2B receptor, low-dose therapy, mood disorders, valvular heart disease, exposure-response model, outpatient treatment, psilocin, clinical safetyhttps://mindmedicinelaw.com/briefing/esketamine-s-dual-role-in-bariatric-surgery-pain-and-mental-health-20260723-25857The Psychedelic Journalen2026-07-25T22:06:12.898103+00:00Esketamine's Dual Role in Bariatric Surgery: Pain and Mental Healthesketamine, bariatric surgery, opioid-free anesthesia, postoperative pain, mental health outcomes, clinical trials, pharmacokinetics, patient care strategies, perioperative risks, surgical recoveryhttps://mindmedicinelaw.com/briefing/psilocybin-mdma-and-memory-new-findings-and-implications-20260723-25425The Psychedelic Journalen2026-07-24T15:05:30.698096+00:00Psilocybin, MDMA and Memory: New Findings and Implicationspsilocybin, MDMA, working memory, neurophysiological activity, clinical trials, psychedelic research, cognitive safety, mental health treatmenthttps://mindmedicinelaw.com/briefing/es-ketamine-s-role-in-functional-neurological-disorder-20260720-24813The Psychedelic Journalen2026-07-24T15:06:01.870278+00:00(Es)ketamine's Role in Functional Neurological Disorderesketamine, functional neurological disorder, systematic review, clinical trials, neuropsychiatric treatment, adverse effects, treatment efficacy, FND symptoms, psychiatric improvement, controlled trialshttps://mindmedicinelaw.com/briefing/esketamine-s-impact-on-anhedonia-insights-from-recent-rct-20260720-24863The Psychedelic Journalen2026-07-24T15:05:52.890192+00:00Esketamine's Impact on Anhedonia: Insights from Recent RCTesketamine, anhedonia, randomized controlled trial, psychiatric disorders, NMDA receptor, treatment-resistant depression, peer review, clinical validation, psychedelic research, therapeutic potentialhttps://mindmedicinelaw.com/briefing/blood-nfl-as-a-biomarker-in-neuro-trials-promise-and-challenges-20260720-24870The Psychedelic Journalen2026-07-24T15:05:43.176752+00:00Blood NfL as a Biomarker in Neuro Trials: Promise and Challengesneurofilament light chain, biomarker, neurodegenerative diseases, clinical trials, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, surrogate endpoint, treatment response, axonal injuryhttps://mindmedicinelaw.com/briefing/nested-boundary-model-psychedelic-impact-on-mind-states-20260719-25162The Psychedelic Journalen2026-07-24T15:06:18.293669+00:00Nested-Boundary Model: Psychedelic Impact on Mind Statesnested-boundary model, psychedelic risk profiles, Markov blankets, analytic idealism, psychological states, neuroscience research, clinical trials, boundary permeability, integrative coherence, mental healthhttps://mindmedicinelaw.com/briefing/neurobiology-of-trauma-implications-for-ptsd-treatment-20260717-24818The Psychedelic Journalen2026-07-24T15:06:29.282379+00:00Neurobiology of Trauma: Implications for PTSD TreatmentPTSD, neurobiology, amygdala hyperreactivity, HPA axis dysregulation, trauma-informed care, clinical practice, autonomic dysregulation, hypocortisolism, evidence-based interventions, mental health policy